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  Orthopaedic and trauma device-related infection (ODRI) 
remains one of the major complications in modern trauma 
and orthopaedic surgery.
  Despite best practice in medical and surgical manage-
ment, neither prophylaxis nor treatment of ODRI is effec-
tive in all cases, leading to infections that negatively 
impact clinical outcome and significantly increase health-
care expenditure.
  The following review summarises the microbiological pro-
file of modern ODRI, the impact antibiotic resistance has 
on treatment outcomes, and some of the principles and 
weaknesses of the current systemic and local antibiotic 
delivery strategies.
  The emerging novel strategies aimed at preventing or treat-
ing ODRI will be reviewed. Particular attention will be paid 
to the potential for clinical impact in the coming decades, 
when such interventions are likely to be critically important.
  The review focuses on this problem from an interdisciplin-
ary perspective, including basic science innovations and 
best practice in infectious disease.
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Introduction
Orthopaedic and trauma device-related infection (ODRI) 
remains a major complication in modern trauma and 
orthopaedic surgery.1 Despite best practice in medical 
and surgical management, neither prophylaxis nor treat-
ment of ODRI is effective in all cases, and can lead to infec-
tions that negatively impact clinical outcome and 
significantly increase healthcare expenditure.2 Pre-opera-
tive and correctly-timed prophylactic antibiotic interven-
tion is mandatory for a majority of orthopaedic procedures. 
However, despite this, the incidence of infection following 
elective orthopaedic surgery is in the range of 0.7% to 
4.2%,3-7 while the incidence can be much higher in trauma 
cases where infection rates range from approximately 1% 
after operative fixation of closed low-energy fractures, to 
more than 30% in complex open tibia fractures.8,9 Treat-
ment success rates vary, with between 57% and 88% 
often reported.10-12 Current curative approaches (radical 
debridement, revision surgery and prolonged antibiotic 
therapy) often result in significant socioeconomic costs, 
not to mention the risk of life-long functional impairment 
for the patient. Against this background, and with the 
increasing issue of antibiotic-resistant bacteria, the prob-
lem of ODRI is set to continue to pose a challenge for prac-
tising clinicians in the coming decades.
The clinical and microbiological challenges 
of modern device-related infections
The most prevalent species in ODRIs are Staphylococci.13-17 
Staphylococcus (S.) aureus accounts for between 20% and 
30% of cases of infection after fracture fixation and pros-
thetic joint infections (PJI), with coagulase-negative staphy-
lococci (CoNS) accounting for 20%–40% of cases,13-16 
including small colony variants.18 Other Gram-positive cocci 
including Streptococci (1%–10%) and Enterococci (3%–
7%) are less frequently encountered. Infections caused by 
Gram-negative bacilli, including Pseudomonas aeruginosa 
and Enterobacteriaceae account for approximately 6%–
17%,13-17 and anaerobes (including Propionibacteria and 
Peptostreptococci) are comparatively rare at approximately 
4%–5%.13-17 Shoulder ODRIs, however, may have higher 
Propionibacterium (P.) acnes prevalence, at up to 38%.19 
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Recently, more attention has been focussed upon polymi-
crobial infections, which may account for 10%-20% of 
cases.13,14,17 Furthermore, studies using molecular diagnos-
tic techniques indicate that, in addition, there is a significant 
proportion (5%-34%) of culture-negative infections.13,20,21
Antibiotic resistance
Infections caused by antibiotic-resistant pathogens are a 
major public health concern, and their treatment can be 
challenging.22 With reference to ODRI, bacteria resistant to 
the few antibiotics with proven anti-biofilm activity 
(Rifampicin-resistant staphylococci and ciprofloxacin-resist-
ant Gram-negatives) are among the most difficult patho-
gens to treat. Methicillin-resistant S. aureus (MRSA) has also 
emerged as a significant threat in both the hospital and 
community environment.23 Within the healthcare setting 
alone, MRSA infections are estimated to affect more than 
150 000 patients annually in the European Union (EU), 
resulting in additional in-hospital costs of EUR 380 million 
for EU healthcare systems.24 Between 25% and 32% of infec-
tions after fracture fixation in the United States are caused by 
MRSA,25,26 but this is highly dependent on the local epide-
miology, with lower rates also observed. With limited treat-
ment options, MRSA infections are associated with a higher 
mortality and increased financial costs relative to sensitive 
equivalents.10,27-30 However, this has not been a universal 
finding.31 Recent publications on PJIs stated that treatment 
decisions should focus more on the identified pathogen, 
and not merely on its methicillin resistance.32
The rise of antimicrobial resistance is one of the major 
challenges in the treatment of ODRIs; however, there are 
also many other challenges (Table 1).
State-of-the-art treatment for orthopaedic 
device-related infection
Systemic antibiotic therapy
The goal of any medical strategy for the treatment of ODRI 
should consist of the long-term elimination of pain, 
restoration of function of the affected joint and, in trauma 
cases, consolidation of the fracture with prevention of 
osteomyelitis. Usually this includes a therapeutic approach 
aiming for definite eradication of the micro-organisms 
causing infection, but in some circumstances can entail 
long-term suppressive antibiotic therapy. Hence, each 
treatment must be tailored to the needs and the medical 
conditions of the individual patient.
To date, a curative therapy always includes surgery, 
since antibiotics alone are not capable of eradicating bio-
film infections. The surgical approach varies from debride-
ment with retention of the prosthesis to one-stage or 
two-stage exchange procedures. In fracture care, the cho-
sen operative intervention often depends on the grade of 
fracture healing. An algorithm for choosing the optimal 
procedure has been proposed,6,33 but there are still sub-
stantial differences in procedural preferences between 
countries and institutions. Nevertheless, the therapeutic 
approach should always be decided by an interdiscipli-
nary team comprised of orthopaedic surgeons and infec-
tious disease specialists and/or microbiologists.
High-quality evidence on the choice of antibiotics is 
scarce. Therefore, therapeutic decisions are often based on 
retrospective data, on pharmacokinetic/pharmacodynamic 
principles and on results from animal models. The optimal 
antibiotic should reach high bactericidal concentrations in 
the organic and inorganic bone tissue, on the surface of the 
device and in intracellular compartments. It should be 
active against slow-growing biofilms and against the meta-
bolically quiescent small colony variants. It should have a 
low propensity to induce bacterial resistance and low toxic-
ity towards the patient. In each case, it is essential to know 
which bacteria are responsible for the infection. Hence, 
antibiotics should be withheld until appropriate diagnos-
tics have been performed. Mounting evidence shows that 
routine susceptibility tests that determine the minimal 
inhibitory concentration (MIC) do not reflect the real-life 
susceptibility of the biofilm-embedded bacteria on the sur-
face of the device; antibiotic susceptibility in biofilms can be 
reduced a thousand-fold.34 Therefore, even when bacteria 
are reported as sensitive to an antibiotic, clinicians should 
Table 1. Biggest challenges in the diagnosis and treatment of ODRI
1.Proof of infection and detection of disease-causing pathogen
A considerable number of infections are ‘culture-negative’ despite being clinically apparent.20,21 In some cases, the causative bacteria are difficult to grow because 
they exist in a metabolically less active state as a biofilm. Bacteria may also be difficult to culture when the patient has been empirically treated with antibiotics.21 
In such cases, cessation of all antibiotic therapy for at least two weeks, followed by open biopsy of tissue and sonication of the device, may offer additional 
opportunity to culture the organism.21
This raises the question: can we do better with diagnosis? Establishing the correct diagnosis with a new test would represent a major breakthrough in the field. 
Similarly, rapid, non-invasive diagnostics and those offering pre-operative diagnostics have the potential to change medical and surgical treatment without 
requiring invasive biopsies.
2. Antimicrobial resistance
Multi drug-resistant organisms are becoming increasingly challenging to treat over time. Many reports now exist of pan drug-resistant organisms and extensively 
drug-resistant pathogens such as vancomycin-resistant S. aureus and Enterococcus spp.
3. Persistence and recurrence of infection
One of the major challenges with treatment of a device-associated infection is the reimplantation of the device, which in most cases is required for the function of 
the patient. The issue is that organisms frequently reside in a biofilm state that is not usually completely eradicated or resected during the explantation phase. The 
biofilm tends to be harboured on tiny fragments of necrotic bone known as sequestra, and may also reside within the cortical bone itself. During reimplantation, 
the biofilm-residing bacteria may be liberated and re-enter their planktonic growth phase, resulting in reinfection. This remains one of the great challenges in 
infection surgery.
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be aware that this does not reflect the ability of the antibi-
otic to kill the same bacteria when growing in a biofilm.
The best evidence for antibiotic selection is available for 
staphylococci. For other bacteria (such as streptococci, ente-
rococci, Gram-negatives) the evidence for antibiotic selec-
tion is less clear. Rifampicin is of critical importance in the 
treatment of staphylococci as an anti-staphylococcal biofilm 
antibiotic, and has been associated with a higher rate of 
treatment success.35-37 Rifampicin should never be adminis-
tered by itself due to rapid development of resistance. The 
initial partner antibiotic most often consists of a beta-lactam 
and later switched to a quinolone (historically ciprofloxacin, 
nowadays often levofloxacin).38 In case of quinolone resist-
ance, various other antibiotic partners have been used such 
as fusidic acid,39,40 cotrimoxazole,41 linezolid,42 clindamycin 
or minocycline.31,43 In the case of rifampicin resistance, alter-
native antibiotics are chosen, with one study showing good 
results with moxifloxacin monotherapy.44 Alternatives to 
beta-lactams, for example in the case of methicillin-resistant 
staphylococci, are vancomycin or daptomycin,45 both of 
which are generally well-tolerated.
Great variability in total duration and the time point of 
the switch46 from intravenous to oral antibiotics exists 
between different countries and hospitals. Guidelines rec-
ommend between two and six weeks of initial intravenous 
therapy, according to the circumstances.33 An early switch 
to oral antibiotics does not seem to be associated with a 
worse outcome.47 The total duration of therapy is usually 
between three and six months. Nevertheless, a duration of 
six weeks may be  sufficient.48-50 Long-term suppression 
therapy is used alternatively in cases of inoperable patients, 
multi drug-resistant  bacteria,51 but also in specific fracture 
cases where consolidation of the fracture has not yet 
occurred and the surgical treatment consistent of debride-
ment with implant retention.52 On the other hand, suc-
cessful experiences from single centres with a very short 
duration of systemic antibiotic therapy of less than one 
week, or solely intra-articular application of antibiotics, 
have been reported.46,53
There are still a lot of open questions to be answered 
(Table 2) and high-level evidence studies are urgently 
needed to overcome these gaps in knowledge.
Local antibiotic delivery
The use of biomaterials as carriers, or vehicles, for the 
delivery of antibiotic agents to the site of infection has 
become a regular adjunct in the treatment of ODRIs.54,55 
Local delivery has numerous theoretical advantages over 
systemic delivery, which can offer the potential for signifi-
cant supportive antimicrobial action. Since the antibiotic 
is placed directly at the site of interest, an intact vascular 
system is not required to reach the surgical site, which 
may be particularly beneficial in trauma patients. Local 
delivery can also achieve local concentrations exceeding 
those achievable systemically, while requiring a lower 
total drug amount, thereby not only improving the local 
concentration, but simultaneously reducing the risk of 
systemic toxicity. Interestingly, the local application of 
antibiotics has even been shown in preclinical in vivo stud-
ies to offer protection against bacteria that are resistant to 
the applied antibiotic,56 indicating that local delivery may 
offer some hope for further improvements in antibiotic 
therapy in the face of bacteria resistant to conventional, 
systemic dosing regimens.
The local application of antibiotics in orthopaedic medi-
cine has been described since the 1970s, when gentamicin-
loaded bone cement was first tested in humans.57 Bone 
cement was a convenient vehicle for antibiotic delivery, as 
it was routinely applied in cemented arthroplasties. Gen-
tamicin was identified as a suitable antibiotic due to the fact 
that it was found to withstand the elevated temperatures of 
curing bone cement, and was considered to offer an accept-
able profile against the most common pathogens associ-
ated with ODRI. Antibiotic-loaded bone cements have been 
shown to improve ODRI outcomes.58,59 Bone cement, how-
ever, was not designed in the first instance as an antibiotic 
delivery vehicle. Therefore, the usual pharmacodynamic 
principles governing systemic antibiotic therapy were not 
part of the equation in the advent of antibiotic-loaded bone 
cements. Unfortunately, despite the passage of more than 
four decades since the first use of antibiotic-loaded bone 
cements, pharmacodynamic principles are still not estab-
lished specifically for use in this way. Therefore, it is perhaps 
not surprising that resistance against gentamicin has 
emerged secondary to gentamicin use in local delivery 
vehicles.60,61 The reason for the development of resistance 
is probably the prolonged release of antibiotics at sub-ther-
apeutic levels from local delivery vehicles, which is in direct 
opposition to ideal release kinetics for a concentration 
dependent antibiotic such as gentamicin.62
There are antimicrobial-loaded device surfaces and 
coatings which have passed through the regulatory 
approval process, have been described in clinical stud-
ies,63-65 and may be expected to emerge in greater 
Table 2. Summary of targets required for improvement of treatment outcomes in ODRI
Systemic antibiotic therapy Local antibiotic therapy
•   Improved diagnostic methods to predict bactericidal activity against  
biofilm-embedded bacteria
•   Introduction of guidelines for local delivery (antibiotic agent selection made 
on a species and resistance status)
•   Evidence for timing of antibiotic switching (parenteral vs oral) and  
duration of treatment
•  Establishment of pharmacodynamic principles applicable to local delivery
•  New antibiotics with increased anti-biofilm activity •  Design of local delivery vehicles that attain pharmacodynamic principles
•  Better oral formulations and drugs with less toxicity •  Biomaterials that can accommodate a wider range of antibiotics
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numbers in future. However, a number of critical issues 
must be resolved prior to achieving the maximum benefit 
of local antibiotic delivery vehicles (Table 2).
New approaches for prevention  
and treatment
Active and passive vaccines
Based on its cost-effectiveness, which is unparalleled by any 
other medical intervention, vaccination is an obvious 
approach to prevent, treat and potentially eradicate ODRIs. 
Unfortunately, all efforts to develop an effective vaccine 
against S. aureus, the primary pathogen involved in ODRI, 
have failed for a number of reasons (Table 3).66-68 The most 
prominent reason is that, in contrast to successful bacterial 
vaccines, which to date have exclusively been against tran-
sient flora, S. aureus has co-evolved with mammalian hosts 
to become a human commensal. Thus, all patients have 
some level of acquired immunity against S. aureus prior to 
surgery. However, the protective versus susceptible nature 
of an individual’s immune response against S. aureus at this 
time is virtually unknown. Therefore, a major research focus 
in targeting the immune response is understanding the 
functional role of specific T cells (cellular immunity) and 
antibodies (humoral immunity) in S. aureus infections. To 
this end of vaccine development, several groups have 
described anti-S. aureus immune responses in physiological 
and pathological situations,69-75 in order to elucidate the 
immune proteome of S. aureus.76 Recently, a multiplex 
immunoassay for characterising a patient’s immune 
response was developed against 14 known S. aureus anti-
gens, which was then used to determine if certain antigens 
dominate humoral immunity in a pilot study of patients 
with osteomyelitis versus uninfected controls.75 Measure-
ment of the immune response against S. aureus may help 
guide future prophylaxis and therapy in an era of personal-
ised medicine, and follow-up research is ongoing.
S. aureus is primarily an extracellular pathogen. Thus, 
its clearance from within mammalian hosts is largely 
dependent on neutrophils.77 Importantly for vaccine 
development, this innate immune mechanism has been 
modeled by the opsonophagocytic activity assay (OPA), 
which has been used to quantify S. aureus killing in vitro.78 
However, antigen-specific T-helper cells are critically 
involved in antibody responses, and it is known that Th17 
cells enhance neutrophil function and bacterial clear-
ance.79 Thus, although the role of adaptive immunity for 
protection against S. aureus remains controversial, there is 
a rationale for a human vaccine. For the most part, the 
molecular targets of S. aureus vaccines that have been 
developed so far have been pathogenic determinants (i.e. 
clumping factor A, ClfA80) and virulence factors (i.e. alpha-
toxin81 and coagulases82). Unfortunately, this strategy is 
limited by great redundancy, as S. aureus contains a mul-
titude of factors with similar pathogenic function. Thus, 
neutralising all of them to decrease pathogenicity seems 
unlikely. Alternatively, interests have focussed on S. aureus 
autolysin (Atl), which comprises highly conserved 
 aminidase (Amd) and glucosaminidase (Gmd) subunits. 
Functionally, Atl is known to be essential for cell wall bio-
synthesis and degradation during binary fission.83-85. Atl 
also functions as an adhesin,86 a biofilm enzyme,87 which 
was identified as a potential molecular target of vancomy-
cin88 and has been reported to interfere with the produc-
tion of antibodies in mice.89 Moreover, Amd and Gmd are 
immune-dominant antigens in mice and humans,75,90 and 
pre-clinical vaccine studies have demonstrated significant 
efficacy.91,92
The most common vaccines involve ‘active’ immunisa-
tion of the host with purified molecular constituents of the 
Table 3. Outline status of novel interventional strategies targeting ODRI
Ionic silver Active and passive immunisation  
for S. aureus
Antimicrobial peptides and 
immunomodulatory peptides
Quorum sensing inhibitors and 
biofilm degrading enzymes
Research status and gaps in the knowledge
•   Widely-studied antimicrobial, 
particularly in the experimental 
preclinical phase
•   Comparative studies against 
conventional antibiotic agents are 
required
•   A full understanding of the risk 
factors for the emergence of silver 
resistance is required
•   Has been the focus of industrial 
research strategies for decades
•   Needs full understanding of the 
immune response against S. aureus 
to make real progress
•   Needs full understanding of the 
nature of the S. aureus antigen(s) 
and antibody response
•   Needs to identify appropriate 
patient populations for evaluating 
vaccine efficacy
•   Thousands of peptides described 
from a wide range of sources
•   Potential target for antibiotic-
resistant infections
•   Toxicity at high concentrations a 
concern
•   Require advancement through the 
preclinical translational research 
pathway
•   In vitro and early in vivo studies show 
promise
•   Debate over whether resistance 
against these compounds can 
develop is still ongoing
Current clinical application and future outlook
•   Currently available for limited 
number of orthopaedic devices
•   Clinical data promising, with 
specific application in the most 
challenging cases
•   Outlook: Role in antibiotic-
resistant cases, or for coverage of 
multiple species
•   Numerous clinical trials ongoing
•   To date, no trial shown efficacy in 
terms of reduced incidence
•   Outlook: Great potential for 
treating most challenging cases, 
where even optimal antimicrobial 
strategies have high failure rate
•   Not yet applied in orthopaedic 
setting
•   Currently only available for topical 
application
•   Outlook: Future role for antibiotic-
resistant isolates
•  Not yet clinically applied
•  Still early stage of translation
•   Outlook: Potential novel approach, 
particularly important for resistant 
biofilm infections
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pathogen, and require the host to evolve protective adap-
tive immunity for this non-virulent challenge. An advantage 
of active vaccines is the robustness of the resulting immu-
nity, which includes both cellular and humoral immunity, 
and the potential of life-long immunity from the generation 
of protective memory T cells and B cells. However, the great-
est limitation of active vaccination is its unpredictability in 
individual patients, particularly immune-compromised indi-
viduals from those with established comorbidities (i.e. age-
ing, autoimmunity, obesity and diabetes).93-96 Thus, it is not 
surprising that the two most recent large clinical trials with 
active S. aureus vaccines (StaphVAX (polysaccharide capsu-
lar antigens CP5 and CP8),97 and V710 (IsdB)98) failed to 
meet their primary endpoints. However, what was very sur-
prising was that V710 vaccination was associated with 
increased sepsis, multi-organ failure and death in patients 
undergoing heart valve replacement who developed 
S. aureus infections,98 which is consistent with the finding 
that high titres of anti-IsdB antibodies are associated with 
these adverse events in total joint arthroplasty patients.75 
This observation raises a new concern that some anti-S. 
aureus immune responses exacerbate infection and/or its 
sequelae, and that additional pre-clinical testing is needed 
to confirm a vaccine’s mechanism of action. It also supports 
transfusion of purified functional anti-S. aureus antibodies as 
a passive immunisation, which is a safer and more predicta-
ble vaccine approach. However, it should be noted that pas-
sive S. aureus vaccines such as Altastaph,99 Veronate,100,101 
Aurexis,80,102 Aurograb103-104 and Pagibaximab,105,106 have 
also failed in clinical trials.
Silver
The significant difficulties involved in the treatment of 
established biofilms prompted research on engineering 
device surfaces that could resist microbial colonisation. Sil-
ver is a potent candidate for coating devices, as it provides 
a broad spectrum of antibacterial activity against plank-
tonic and sessile, Gram-positive and Gram-negative, and 
also multi drug-resistant bacteria.107 Moreover, it demon-
strates bactericidal efficacy at a low concentration, with 
limited toxicity towards human cells. Silver attacks a broad 
range of bacterial targets by interfering with thiol and 
amino groups of proteins, with nucleic acids and cell 
membranes. The disruption of iron-sulphur clusters seems 
to be particularly detrimental for the affected organism, 
producing reactive oxygen species and inhibiting the res-
piratory chain.108-110
Silver has been used as a  disinfectant for many centu-
ries.111 From the 19th century onwards, silver was employed, 
among other uses, in the prevention of gonorrhoeal oph-
thalmia (Crédé prophylaxis), as suture material, or as oint-
ment to treat wound infections.111,112 Currently, 
technological advances have created many new formula-
tions of silver, which are either still under development, or 
already deployed for commercial and medical purposes. 
Silver is used in its metallic form as a nanoparticle, or silver-
containing polymers and composites.113,114 For orthopaedic 
applications, silver has been introduced into hydroxyapatite 
and bone cement, and as a coating for trauma devices.115 
Most formulations exert good antimicrobial properties. 
Nevertheless, the heterogeneity of materials and methods 
make direct comparison of the antimicrobial effect difficult. 
Recently, new compounds called silver oxynitrate 
(Ag(Ag3O4)2NO3 or Ag7NO11) showed a better effect against 
bacterial biofilms than other formulations (Ag2SO4, AgNO3, 
silver sulfadiazine (AgSD), AgO, Ag2O).116
Primary clinical studies are promising, demonstrating a 
trend in reducing infection with silver-coated central 
venous catheters,117 urinary catheters118 and ventilator 
endotracheal tubes.119 Similar results were achieved with 
silver-coated external fixation pins,120 proximal femur or 
tibia megaprostheses64 and tumour prostheses.121
One of the major concerns associated with the use of an 
antimicrobial substance is the development and spread of 
resistant mutants. Indeed, development of resistance to 
silver was reported in relation to P. aeruginosa as early as 
1966.122 Thereafter, many publications have demonstrated 
widespread occurrence of silver resistance in Enterobacte-
riaceae, but interestingly never in Gram-positive bacteria. 
These data strengthen the notion that the concerted action 
against intracellular silver is so far neither known to be 
inherent nor inducible for Gram-positive bacteria, which 
makes silver coatings controversial for clinical use.
The toxicity of silver to eukaryotic cells has been another 
concern.112 However, the health risk in exposed humans 
seems to be low, and consists mostly of a discolouration of 
the skin and eyes due to silver deposition called argyria 
and argyrosis, respectively.123-125 Nevertheless, few case 
reports exist of neural or other systemic toxicity after high 
exposure to silver.126,127 In this context, the potent new sil-
ver formulations should be tested in solid in vitro and 
in  vivo toxicity studies. Accordingly, the potential of 
osseointegration of silver-coated prostheses needs further 
exploration. However, the available evidence in this respect 
is encouraging.128 Finally, one of the biggest hurdles in 
designing a silver-coated surface is the controlled release 
of silver. Data on silver release kinetics are mostly lacking, 
but crucial for defining the optimal clinical application. 
With further development, knowledge and optimisation of 
formulations, silver seems a promising addition to our 
antibacterial arsenal in the fight against device infection.
Antimicrobial and anti-biofilm peptides
Antimicrobial peptides (AMPs) are innate defence mole-
cules of animals, plants and microorganisms, with a broad 
spectrum of antimicrobial activity and low risk of resistance 
development in general.129,130 The low risk of resistance 
development is due to the fact that AMPs interact with 
microbial membranes, resulting in membrane depolarisa-
tion, destabilisation and/or disruption leading to rapid cell 
death, or passing of the membrane to reach intracellular 
targets.131 Native AMPs have been used as design templates 
for a large variety of synthetic AMPs, some of which have 
now reached the stage of phase 2 and 3 clinical trials.132
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Several AMPs also have the capacity to prevent biofilm 
formation. A recent study by Mansour et  al133 demon-
strated that a synthetic peptide (named 1018) inhibited 
biofilm formation by S. aureus and multiple other species 
by blocking (p)ppGpp, an important signal in biofilm 
development, at concentrations that did not affect bacte-
rial growth. A peptide derived from CRAMP (the mouse 
homologue of the human defence peptide LL-37 (catheli-
cidin), showed inhibition of biofilm formation of the yeast 
Candida albicans, and also prevented biofilm formation 
by different bacterial species.134 Many more examples of 
AMPs with anti-biofilm activity have recently been listed in 
the specialised biofilm-active antimicrobial peptides 
(BaAMPs) database.135
Application of AMPs to biomaterials
Immobilisation of AMPs on surfaces has been performed 
with a variety of peptides, and many different chemistries. 
A good overview of immobilisation strategies has been 
published by Costa et  al.136 For peptides to be effective 
after immobilisation, they should retain the structural 
characteristics important for their antimicrobial activity. 
Other decisive factors for success are length, flexibility, 
and kind of spacer connecting the peptide to the surface, 
the AMP surface density and the orientation of the immo-
bilised peptides.136 Although peptides are considered to 
be active through insertion into the microbial membranes, 
even short surface-attached peptides, which are unlikely 
to have a free interaction with the membrane, have anti-
microbial activity.137 This activity is thought to be due to 
destabilisation of the membrane by displacement of posi-
tively charged counter-ions, changing bacterial surface 
electrostatics and activating autolytic enzymes or disrupt-
ing the ionic balance.137
Chemical procedures of tethering AMPs to surfaces 
may cause a strong decrease in their antimicrobial activity 
or even inactivation,138,139 depending on the combination 
of peptides and immobilisation technology. A recent, 
novel approach of attaching peptides to hydrogels used 
for surface coating is the application of thiol-ene chemis-
try allowing a fast, single-step immobilisation strategy.140 
Using this strategy, mimics of the HHC-10 peptide141 with 
optimal plasma stability were attached to a polymer 
surface. These surfaces killed inocula of S. aureus, S taphy-
lococcus epidermidis and Escherichia coli with high effi-
ciency in vitro.140
Controlled release coatings for orthopaedic and trauma 
devices, for example, are designed to provide a burst 
release of an antimicrobial agent during the first days after 
implantation, preferably followed by a continuous release 
providing local protective levels during several weeks 
after implantation. The incorporation of AMPs in such 
coatings has not yet been extensively developed. In a 
recent study, a polymer lipid encapsulation matrix (PLEX) 
coating designed for doxycycline release from a bone 
filler142 was tailored to such a preferred release profile. The 
doxycycline-PLEX coating prevented osteomyelitis caused 
by S. aureus in a rabbit model.56 Based on these studies, 
PLEX coatings containing the novel AMPs were recently 
developed successfully. These coatings show potent anti-
microbial activity, prevent biofilm formation and prevent 
S. aureus infection of subcutaneous implants in mice (Zaat 
et al143).
Quorum-sensing inhibitors and biofilm-degrading enzymes
Quorum sensing (QS) is a mechanism that many microor-
ganisms use to coordinate gene expression in populations 
in response to local conditions, including cell density.144 The 
canonical QS system consists of one or more proteins 
involved in producing and transporting the signalling mol-
ecule, the actual signalling molecule, a receptor for the sig-
nalling molecule and, in some QS systems, additional 
regulatory proteins.144 The most-studied systems are those 
that use N-acyl homoserine lactones (AHL) as signalling 
molecules (present in many Gram-negative bacteria, includ-
ing P. aeruginosa) and the QS system in S. aureus in which 
auto-inducing peptides (AIP) are used as signalling 
 molecules.144 In many organisms, biofilm formation is  (co-)
regulated by QS, making the latter process an interesting 
target for novel approaches to antimicrobial chemotherapy 
in biofilm infections such as ODRI.144,145 In addition, it is 
well-known from early work in this field that, in at least 
some microorganisms, QS is involved in tolerance to antimi-
crobial agents and the immune system.146,147 These obser-
vations suggested that combining a conventional 
antimicrobial agent with a quorum-sensing inhibitor (QSI) 
might circumvent the problem of biofilm tolerance.
Experimental evidence for this approach has been pro-
vided in several studies in which it was shown that combin-
ing antibiotics with QSI increased the success of treatment 
in different model systems. This was true for various organ-
isms (including S. aureus and P. aeruginosa) and for differ-
ent antibiotic/QSI combinations (including the combination 
vancomycin/hamamelitannin against S.  aureus and 
tobramycin/furanone C-30 against P. aeruginosa).148,149 
While the QSI described in the literature are extremely 
diverse in structure, they can be grouped according to their 
target. A first approach to inhibit QS is the enzymatic deg-
radation of the AHL signalling molecules, by using specific 
AHL lactonases or acylases produced by bacteria.145 Also 
paraoxonases found in human serum and expressed in vari-
ous cell types can degrade AHLs.145 A second group of QSIs 
target the synthesis of the signal molecule. From studies 
investigating the role of QS-related genes in biofilm forma-
tion, we know that mutant strains in which genes involved 
in the synthesis of the signalling molecule(s) are inacti-
vated, are affected in biofilm formation. This is, for exam-
ple, the case in Burkholderia cenocepacia cepI and cciI 
mutants (both CepI and CciI are AHL-synthases)150 and in S. 
aureus mutants that are defective in producing AIP.151 Con-
sidering the biosynthesis pathway of AHLs, inhibitors of 
S-adenosylmethionine and fatty acid biosynthesis (including 
sinefungin and 5-methylthioadenosine) may be used as 
QSIs.145 Less is known about QSI targeting AIP synthesis, 
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although inhibitors of the type-I signal peptidase SpsB that 
reduce AIP production have been described.151 Finally, 
compounds targeting the QS receptors and/or signal ana-
logues can act as QSI. Many AHL analogues (with modifica-
tions in the acyl side chain, the central amide moiety, and/
or the lactone ring) have been synthesised and tested, and 
many of these interfere with the process of biofilm forma-
tion. For example, application of AHL in which the central 
amide moiety was replaced by triazolylhydrofuranones 
resulted both in biofilm inhibition and biofilm eradication in 
a number of Gram-negative pathogens, including P. aer-
uginosa.152 One of the most-studied QSIs with activity 
against S. aureus also targets the QS receptor: the RNAIII-
inhibiting peptide (RIP), several of its analogues and the 
non-peptide analogue hamamelitannin are thought to 
interfere with the RAP/TRAP QS system in S. aureus, and by 
doing so to affect biofilm formation and increase biofilm 
susceptibility towards antibiotics.148,151 So far most of the 
studies on QSIs as anti-biofilm agents have been carried out 
using in vitro model systems, or in simple in vivo mod-
els.148,153 In a limited number of studies, QSIs were tested 
using animal models, for example in a mouse model for 
pulmonary infection (with B. cenocepacia)148 or for skin 
infection (with S. aureus).154 However, to our knowledge, 
testing of QSIs in an appropriate animal model for ortho-
paedic device-associated biofilm infections has not yet been 
done, although several foreign body models mimicking 
biofilm infections on prosthetic devices are available.155,156
A second innovative anti-biofilm strategy depends on 
the use of biofilm-degrading enzymes, and both deoxyri-
bonuclease I (DNase I) and exopolysaccharide-degrading 
dispersin B (DspB), which could have applications in the 
prevention or treatment of biofilm infections associated 
with orthopaedic devices.157,158 Extracellular DNA (eDNA) 
is a key component of many microbial biofilms, and the 
use of DNase I leads to the disruption of pre-existing bio-
films in many species, as well as an increased susceptibil-
ity to antimicrobial agents.159 In addition, biofilm 
formation is inhibited in some species by the presence of 
DNase I.159 However, this is not the case for all bacteria 
tested, and the effect on pre-existing biofilms is also spe-
cies and biofilm age-dependent.159 DspB is a 
β-hexosaminidase capable of degrading poly-(β-1,6)-N-
acetylglucosamine, an exopolysaccharide that is an impor-
tant component of the biofilm matrix in various 
organisms.157,158 Application of DspB resulted in biofilm 
dispersal and detachment, and when combined with con-
ventional antimicrobial agent, DspB showed syner-
gism.157,158,160 In the context of PJIs, it is interesting to see 
that DspB overall has good activity against staphylococcal 
biofilms157,158 and that its activity is maintained in vivo (at 
least in a subcutaneous implant model for S. aureus infec-
tions in a rabbit).160 In addition, DspB-loaded coatings 
were shown to inhibit S. epidermidis biofilm formation in 
vitro, without affecting the attachment or growth of cul-
tured human osteoblasts, suggesting that such coatings 
hold promise for developing medical devices with anti-
biofilm properties.161
Summary and outlook
ODRI remains one of the most challenging complications 
in orthopaedics. A wide range of treatment options are 
available, although the established guidelines and algo-
rithms have improved standardisation and outcomes. 
However, improvements in preventative and therapeutic 
strategies are required, as current practices are not com-
pletely effective. This is particularly critical considering the 
increasing challenge of antibiotic-resistant bacteria.
Emerging technologies and interventions may be 
expected to improve treatment success in the future 
(Table  3). Crucially, research strategies have focussed on 
antibiotic resistance and biofilm formation as targets for 
future interventional strategies. These interventions have the 
potential to reduce infection rates and improve treatment 
outcomes, if and when these interventions make it to clinical 
practice. Few regulatory body-approved antibiotic-function-
alised orthopaedic and trauma devices are currently availa-
ble; however this may yet grow in the coming decades, 
provided they pass a robust preclinical evaluation and 
emerge onto the market with a proven ability to improve 
outcome in the prevention and treatment of ODRIs.
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